Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Wan, Zhitao ^a,b   Chen, Xulin ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b Novartis Institutes for Biomedical Research   (China)

Author keywords

Antiviral; HIV 1; Proteasomal degradation; Tat; Triptolide

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ELONGATION FACTOR 1ALPHA; TRANSACTIVATOR PROTEIN; TRIPTOLIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DITERPENE; EPOXIDE; PHENANTHRENE DERIVATIVE; PROTEASOME;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LONG TERMINAL REPEAT; LUCIFERASE ASSAY; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION PROFILING; METABOLISM; PHYSIOLOGY; TRIPTERYGIUM; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS 1; TRIPTERYGIUM WILFORDII;

ANTI-HIV AGENTS; BLOTTING, WESTERN; DITERPENES; EPOXY COMPOUNDS; GENE EXPRESSION PROFILING; GENE PRODUCTS, TAT; HIV-1; HUMANS; PHENANTHRENES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; TRIPTERYGIUM; VIRUS REPLICATION;

EID: 84934966187     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0088-6     Document Type: Article

References (43)

1. Volberding PA, Deeks SG: Antiretroviral therapy and management of HIV infection. Lancet 2010, 376(9734):49-62.
2. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000, 356(9239):1423-1430.
3. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J: The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008, 118(4):1244-1254.
4. Montessori V, Press N, Harris M, Akagi L, Montaner JSG: Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J 2004, 170(2):229-238.
5. Pierson T, McArthur J, Siliciano RF: Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000, 18(1):665-708.
6. Cullen BR: Regulation of HIV-1 gene expression. FASEB J 1991, 5(10):2361-2368.
7. Barboric M, Peterlin BM: A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. PLoS Biol 2005, 3(2):e76.
8. Karn J: Tackling tat. J Mol Biol 1999, 293(2):235-254.
9. Wei P, Garber ME, Fang S-M, Fischer WH, Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998, 92(4):451-462.
10. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH: Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev 1997, 11(20):2622-2632.
11. Price DH: P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000, 20(8):2629-2634.
12. Stevens M, De Clercq E, Balzarini J: The regulation of HIV-1 transcription: Molecular targets for chemotherapeutic intervention. Med Res Rev 2006, 26(5):595-625.
13. Baba M: Recent status of HIV-1 gene expression inhibitors. Antiviral Res 2006, 71(2-3):301-306.
14. Massari S, Sabatini S, Tabarrini O: Blocking HIV-1 replication by targeting the Tat-hijacked transcriptional machinery. Curr Pharm Des 2013, 19(10):1860-1879.
15. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, Karn J, Klimkait T: An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci 1997, 94(8):3548-3553.
16. Chao S, Fujinaga K, Marion J, Taube R, Sausville E, Senderowicz A, Peterlin B, Price D: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000, 275:28345-28348.
17. Davis B, Afshar M, Varani G, Murchie AIH, Karn J, Lentzen G, Drysdale M, Bower J, Potter AJ, Starkey ID, Swarbrick T, Aboul-ela F: Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots". J Mol Biol 2004, 336(2):343-356.
18. Murchie AIH, Davis B, Isel C, Afshar M, Drysdale MJ, Bower J, Potter AJ, Starkey ID, Swarbrick TM, Mirza S, Prescott CD, Vaglio P, Aboul-ela F, Karn J: Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J Mol Biol 2004, 336(3):625-638.
19. Davidson A, Leeper TC, Athanassiou Z, Patora-Komisarska K, Karn J, Robinson JA, Varani G: Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci 2009, 106(29):11931-11936.
20. Lalonde MS, Lobritz MA, Ratcliff A, Chamanian M, Athanassiou Z, Tyagi M, Wong J, Robinson JA, Karn J, Varani G, Arts EJ: Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog 2011, 7(5):e1002038.
21. Hamasaki T, Okamoto M, Baba M: Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interaction. Antimicrob Agents Chemother 2013, 57(3):1323-1331.
22. Guendel I, Iordanskiy S, Van Duyne R, Kehn-Hall K, Saifuddin M, Das R, Jaworski E, Sampey GC, Senina S, Shultz L, Narayanan A, Chen H, Lepene B, Zeng C, Kashanchi F: Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication. J Virol 2014, 88(2):1189-1208.
23. Liu Q: Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011, 11(3):377-383.
24. Zhang X, Pais GCG, Svarovskaia ES, Marchand C, Johnson AA, Karki RG, Nicklaus MC, Pathak VK, Pommier Y, Burke TR Jr: Azido-containing aryl β-dketo acid HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2003, 13(6):1215-1219.
25. Ciechanover A: Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005, 6(1):79-87.
26. Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8(10):397-403.
27. Seglen PO, Grinde B, Solheim AE: Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupepti. Eur J Biochem 1979, 95(2):215-225.
28. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin M-H, Jans DA, Harrich D: Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol 2009, 83(22):11694-11703.
29. Favre D, Studer E, Michel MR: Two nucleolar targeting signals present in the N-terminal part of Semliki Forest virus capsid protein. Arch Virol 1994, 137(1-2):149-155.
30. Stauber RH, Pavlakis GN: Intracellular trafficking and interactions of the HIV-1 Tat protein. Virology 1998, 252(1):126-136.
31. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC-H, Kao PN: Immunosuppressant PG490 (Triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-κB transcriptional activation. J Biol Chem 1999, 274(19):13443-13450.
32. Pande V, Ramos MJ: Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. Curr Med Chem 2003, 10(16):1603-1615.
33. Wang Y, Lu J-J, He L, Yu Q: Triptolide (TPL) inhibits global transcription by Inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS One 2011, 6(9):e23993.
34. Titov DV, Gilman B, He Q-L, Bhat S, Low W-K, Dang Y, Smeaton M, Demain AL, Miller PS, Kugel JF, Goodrich JA, Liu JO: XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011, 7(3):182-188.
35. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ: A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res 2000, 28(3):663-668.
36. Rohr O, Marban C, Aunis D, Schaeffer E: Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 2003, 74(5):736-749.
37. Imai K, Asamitsu K, Victoriano AFB, Cueno ME, Fujinaga K, Okamoto T: Cyclin T1 stabilizes expression levels of HIV-1 Tat in cells. FEBS J 2009, 276(23):7124-7133.
38. Jadlowsky J, Nojima M, Schulte A, Geyer M, Okamoto T, Fujinaga K: Dominant negative mutant Cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat. Retrovirology 2008, 5(1):63.
39. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006, 108(2):630-637.
40. Chang W-T, Kang JJ, Lee K-Y, Wei K, Anderson E, Gotmare S, Ross JA, Rosen GD: Triptolide and chemotherapy cooperate in tumor cell apoptosis: a role for the p53 pathway. J Biol Chem 2001, 276(3):2221-2227.
41. Westerheide SD, Kawahara TLA, Orton K, Morimoto RI: Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006, 281(14):9616-9622.
42. Wan H, Seth A, Rainen L, Fernandes H: Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA. J Clin Microbiol 2010, 48(6):2186-2190.
43. Miyake A, Ishida T, Yamagishi M, Hara T, Umezawa K, Watanabe T, Horie R: Inhibition of active HIV-1 replication by NF-κB inhibitor DHMEQ. Microbes Infect 2010, 12(5):400-408.